Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E. Santonja A, et al. Among authors: ramirez tortosa cl. Oncotarget. 2018 May 29;9(41):26406-26416. doi: 10.18632/oncotarget.25413. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899867 Free PMC article.
Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E. Sánchez-Muñoz A, et al. Oncology. 2012;83(4):228-33. doi: 10.1159/000341537. Epub 2012 Aug 16. Oncology. 2012. PMID: 22907070
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11. Clin Breast Cancer. 2013. PMID: 23318089 Clinical Trial.
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Sánchez-Muñoz A, Plata-Fernández Y, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Pascual J, Alba E, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Clin Transl Oncol. 2014 Jun;16(6):548-54. doi: 10.1007/s12094-013-1116-z. Epub 2013 Oct 2. Clin Transl Oncol. 2014. PMID: 24085576 Clinical Trial.
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, Miramón J, Zarcos I, Ramírez-Tortosa CL, Montes-Torres J, Jerez JM, de Luque V, Llácer C, Fernández-De Sousa CE, Pérez-Villa L, Alba E. Sánchez-Muñoz A, et al. Mod Pathol. 2018 Feb;31(2):299-306. doi: 10.1038/modpathol.2017.129. Epub 2017 Oct 6. Mod Pathol. 2018. PMID: 28984296 Free article.
Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.
Ramírez-Tortosa CL, Alonso-Calderón R, Gálvez-Navas JM, Pérez-Ramírez C, Quiles JL, Sánchez-Rovira P, Jiménez-Morales A, Ramírez-Tortosa M. Ramírez-Tortosa CL, et al. Cancers (Basel). 2022 Nov 2;14(21):5393. doi: 10.3390/cancers14215393. Cancers (Basel). 2022. PMID: 36358811 Free PMC article.
A plasma metabolomic signature discloses human breast cancer.
Jové M, Collado R, Quiles JL, Ramírez-Tortosa MC, Sol J, Ruiz-Sanjuan M, Fernandez M, de la Torre Cabrera C, Ramírez-Tortosa C, Granados-Principal S, Sánchez-Rovira P, Pamplona R. Jové M, et al. Oncotarget. 2017 Mar 21;8(12):19522-19533. doi: 10.18632/oncotarget.14521. Oncotarget. 2017. PMID: 28076849 Free PMC article.
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. González-González A, et al. Among authors: ramirez tortosa cl. Clin Cancer Res. 2018 Nov 15;24(22):5697-5709. doi: 10.1158/1078-0432.CCR-17-3125. Epub 2018 Jul 16. Clin Cancer Res. 2018. PMID: 30012564
Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study.
Vieites B, López-García MÁ, Martín-Salvago MD, Ramirez-Tortosa CL, Rezola R, Sancho M, López-Vilaró L, Villardell F, Burgués O, Fernández-Rodriguez B, Alfaro L, Peg V. Vieites B, et al. Among authors: ramirez tortosa cl. Clin Transl Oncol. 2021 Jul;23(7):1377-1385. doi: 10.1007/s12094-020-02530-4. Epub 2021 Jan 31. Clin Transl Oncol. 2021. PMID: 33517542 Free PMC article.
Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Martínez-Ortega E, Fernández Morales M, Fernández-Navarro M, de la Torre Cabrera C, Dueñas B, Ureña C, Martínez J, Morales F, Ramírez-Tortosa C, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Breast J. 2008 Sep-Oct;14(5):506-7. doi: 10.1111/j.1524-4741.2008.00634.x. Epub 2008 Aug 13. Breast J. 2008. PMID: 18705667 No abstract available.
55 results